TY  - JOUR
AU  - Pejović, Janko
AU  - Ignjatović, Svetlana
AU  - Dajak, Marijana
AU  - Majkić-Singh, Nada
AU  - Vučinić, Žarko
AU  - Pavlović, Miroslav
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1854
AB  - Background/Aim. Identification of patients with arterial hypertension and a possible onset of heart failure by determining the concentration of N-terminal pro-B-type natriuretic peptide (NT-proBNP) enables timely intensification of treatment and allows clinicians to prescribe and implement optimal and appropriate care. The aim of this study was to evaluate NT-proBNP in patients with longstanding hypertension and in patients with signs of hypertensive cardiomyopathy. Methods. The study involved 3 groups, with 50 subjects each: "healthy" persons (control group), patients with hypertension and normal left ventricular systolic function (group 1) and patients with longstanding hypertension and signs of hypertensive cardiomyopathy with impaired left ventricular systolic function (group 2). We measured levels of NT-proBNP, C-reactive protein and creatinine according to the manufacturer's instructions. All the patients were clinically examined including physical examination of the heart with blood pressure, pulse rate, electrocardiogram (ECG) and echocardiogram. Results. Our results showed that the determined parameters generally differed significantly (Student's t-test) among the groups. The mean (+/- SD) values of NT-proBNP in the control group, group 1 and group 2 were: 2.794 (+/- 1.515) pmol/L, 9.575 (+/- 5.449) pmol/L and 204.60 (84,93) pmol/L, respectively. NT-proBNP correlated significantly with the determined parameters both in the group 1 and the group 2. In the group 1, the highest correlation was obtained with C-reactive protein (r = 0.8424). In the group 2, the highest correlation was obtained with ejection fraction (r = -0.9111). NT-proBNP showed progressive increase in proportion to the New York Heart Association (NYHA) classification. The patients in the- group 2 who belonged to the II and III NYHA class had significantly higher levels of NT-proBNP than those in the NYHA class I (ANOVA test,p = 0.001). Conclusion. The obtained results suggest that NT-proBNP is a useful biomarker in the treatment of patients with longstanding hypertension who are at risk for heart failure.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Correlation of N-terminal pro-B-type natriuretic peptide with clinical parameters in patients with hypertension
VL  - 70
IS  - 8
SP  - 728
EP  - 734
DO  - 10.2298/VSP110322048P
ER  - 

@article{
author = "Pejović, Janko and Ignjatović, Svetlana and Dajak, Marijana and Majkić-Singh, Nada and Vučinić, Žarko and Pavlović, Miroslav",
year = "2013",
abstract = "Background/Aim. Identification of patients with arterial hypertension and a possible onset of heart failure by determining the concentration of N-terminal pro-B-type natriuretic peptide (NT-proBNP) enables timely intensification of treatment and allows clinicians to prescribe and implement optimal and appropriate care. The aim of this study was to evaluate NT-proBNP in patients with longstanding hypertension and in patients with signs of hypertensive cardiomyopathy. Methods. The study involved 3 groups, with 50 subjects each: "healthy" persons (control group), patients with hypertension and normal left ventricular systolic function (group 1) and patients with longstanding hypertension and signs of hypertensive cardiomyopathy with impaired left ventricular systolic function (group 2). We measured levels of NT-proBNP, C-reactive protein and creatinine according to the manufacturer's instructions. All the patients were clinically examined including physical examination of the heart with blood pressure, pulse rate, electrocardiogram (ECG) and echocardiogram. Results. Our results showed that the determined parameters generally differed significantly (Student's t-test) among the groups. The mean (+/- SD) values of NT-proBNP in the control group, group 1 and group 2 were: 2.794 (+/- 1.515) pmol/L, 9.575 (+/- 5.449) pmol/L and 204.60 (84,93) pmol/L, respectively. NT-proBNP correlated significantly with the determined parameters both in the group 1 and the group 2. In the group 1, the highest correlation was obtained with C-reactive protein (r = 0.8424). In the group 2, the highest correlation was obtained with ejection fraction (r = -0.9111). NT-proBNP showed progressive increase in proportion to the New York Heart Association (NYHA) classification. The patients in the- group 2 who belonged to the II and III NYHA class had significantly higher levels of NT-proBNP than those in the NYHA class I (ANOVA test,p = 0.001). Conclusion. The obtained results suggest that NT-proBNP is a useful biomarker in the treatment of patients with longstanding hypertension who are at risk for heart failure.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Correlation of N-terminal pro-B-type natriuretic peptide with clinical parameters in patients with hypertension",
volume = "70",
number = "8",
pages = "728-734",
doi = "10.2298/VSP110322048P"
}

Pejović, J., Ignjatović, S., Dajak, M., Majkić-Singh, N., Vučinić, Ž.,& Pavlović, M.. (2013). Correlation of N-terminal pro-B-type natriuretic peptide with clinical parameters in patients with hypertension. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 70(8), 728-734.
https://doi.org/10.2298/VSP110322048P

Pejović J, Ignjatović S, Dajak M, Majkić-Singh N, Vučinić Ž, Pavlović M. Correlation of N-terminal pro-B-type natriuretic peptide with clinical parameters in patients with hypertension. in Vojnosanitetski pregled. 2013;70(8):728-734.
doi:10.2298/VSP110322048P .

Pejović, Janko, Ignjatović, Svetlana, Dajak, Marijana, Majkić-Singh, Nada, Vučinić, Žarko, Pavlović, Miroslav, "Correlation of N-terminal pro-B-type natriuretic peptide with clinical parameters in patients with hypertension" in Vojnosanitetski pregled, 70, no. 8 (2013):728-734,
https://doi.org/10.2298/VSP110322048P . .

TY  - JOUR
AU  - Pejović, Janko
AU  - Ignjatović, Svetlana
AU  - Dajak, Marijana
AU  - Majkić-Singh, Nada
AU  - Vučinić, Žarko
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1557
AB  - Patients with hypertensive heart disease have elevated concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). The aim of our study was to evaluate NT-proBNP in patients with long-standing hypertension and in patients with signs of hypertensive cardiomyopathy. The study included three groups of 50 subjects: healthy persons (Control Group), patients with hypertension and normal left ventricular systolic function (Group 1) and patients with long-standing hypertension and signs of hypertensive cardiomyopathy with impaired left ventricular systolic function (Group 2). Our results show a very good correlation (Pearson's test) between NT-proBNP in Group 1 and Group 2 and C-reactive protein (Group 1: r = 0.8424; Group 2: r = 0.6650), systolic blood pressure (Group 1: r = 0.7213; Group 2: r = 0.4856), diastolic blood pressure (Group 1: r = 0.4282; Group 2: r = 0.3989) and ejection fraction (Group 1: r = -0.7390; Group 2: r = 0.9111). ROC analysis revealed that the AUC between the Control Group and Group 1 for NT-proBNP (0.912) was not significantly different (p>0.05) from the AUC for systolic (0.924) and diastolic pressure (0.937). A cut-off value for NT-proBNP of 5.89 pmol/L can be used to reliably distinguish patients of Group 1 from the Control Group, and a cut-off value of 21.67 pmol/L reliably separates patients from Group 1 and Group 2 (in both cases, the AUC is 1.000). Patients in Group 2 who belonged to the II and III New York Heart Association (NYHA) class had significantly higher levels of NT-proBNP than those in NYHA class I (ANOVA test, p=0.001). These data suggest that NT-proBNP is a useful biomarker for distinguishing patients with long-standing hypertension who are at risk of heart failure, allowing optimization and proper treatment of these patients.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease
VL  - 30
IS  - 3
SP  - 244
EP  - 249
DO  - 10.2478/v10011-011-0016-4
ER  - 

@article{
author = "Pejović, Janko and Ignjatović, Svetlana and Dajak, Marijana and Majkić-Singh, Nada and Vučinić, Žarko",
year = "2011",
abstract = "Patients with hypertensive heart disease have elevated concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). The aim of our study was to evaluate NT-proBNP in patients with long-standing hypertension and in patients with signs of hypertensive cardiomyopathy. The study included three groups of 50 subjects: healthy persons (Control Group), patients with hypertension and normal left ventricular systolic function (Group 1) and patients with long-standing hypertension and signs of hypertensive cardiomyopathy with impaired left ventricular systolic function (Group 2). Our results show a very good correlation (Pearson's test) between NT-proBNP in Group 1 and Group 2 and C-reactive protein (Group 1: r = 0.8424; Group 2: r = 0.6650), systolic blood pressure (Group 1: r = 0.7213; Group 2: r = 0.4856), diastolic blood pressure (Group 1: r = 0.4282; Group 2: r = 0.3989) and ejection fraction (Group 1: r = -0.7390; Group 2: r = 0.9111). ROC analysis revealed that the AUC between the Control Group and Group 1 for NT-proBNP (0.912) was not significantly different (p>0.05) from the AUC for systolic (0.924) and diastolic pressure (0.937). A cut-off value for NT-proBNP of 5.89 pmol/L can be used to reliably distinguish patients of Group 1 from the Control Group, and a cut-off value of 21.67 pmol/L reliably separates patients from Group 1 and Group 2 (in both cases, the AUC is 1.000). Patients in Group 2 who belonged to the II and III New York Heart Association (NYHA) class had significantly higher levels of NT-proBNP than those in NYHA class I (ANOVA test, p=0.001). These data suggest that NT-proBNP is a useful biomarker for distinguishing patients with long-standing hypertension who are at risk of heart failure, allowing optimization and proper treatment of these patients.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease",
volume = "30",
number = "3",
pages = "244-249",
doi = "10.2478/v10011-011-0016-4"
}

Pejović, J., Ignjatović, S., Dajak, M., Majkić-Singh, N.,& Vučinić, Ž.. (2011). N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 30(3), 244-249.
https://doi.org/10.2478/v10011-011-0016-4

Pejović J, Ignjatović S, Dajak M, Majkić-Singh N, Vučinić Ž. N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease. in Journal of Medical Biochemistry. 2011;30(3):244-249.
doi:10.2478/v10011-011-0016-4 .

Pejović, Janko, Ignjatović, Svetlana, Dajak, Marijana, Majkić-Singh, Nada, Vučinić, Žarko, "N-terminal pro-b-type natriuretic peptide in patients with hypertensive heart disease" in Journal of Medical Biochemistry, 30, no. 3 (2011):244-249,
https://doi.org/10.2478/v10011-011-0016-4 . .